Download PDF
CC BY 4.0 · Journal of Child Science 2021; 11(01): e80-e82
DOI: 10.1055/s-0041-1726462
Case Report

Reintroduction of Diazoxide after Diagnosis of Pulmonary Hypertension in a Patient with Transient Hyperinsulinism

Bahareh Schweiger
1   Pediatrics Department, Cedars-Sinai Hospital, Los Angeles, California, United Sates
,
Pedro A. Sanchez-Lara
1   Pediatrics Department, Cedars-Sinai Hospital, Los Angeles, California, United Sates
,
Dor Markush
2   Guerin Congenital Heart Program, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United Sates
,
Pooja Nawathe
1   Pediatrics Department, Cedars-Sinai Hospital, Los Angeles, California, United Sates
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Our case describes the reintroduction of diazoxide despite life-threatening pulmonary hypertension in our infant due to lack of therapeutic options for congenital hyperinsulinism.

Keywords

congenital hyperinsulinism - diazoxide - pulmonary hypertension - chlorothiazide - side effects

Authors' Contributions

P.N. has made substantial contributions to the conception and design of the work; and helped in drafting the work and substantively revised it and has approved the submitted version and has agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

B.S. made substantial contributions to the conception and design of the work; and helped in drafting the work and substantively revised it and has approved the submitted version and has agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.




Publication History

Received: 16 November 2020

Accepted: 10 February 2021

Article published online:
01 April 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Silvani P, Camporesi A, Mandelli A, Wolfler A, Salvo I. A case of severe diazoxide toxicity. Paediatr Anaesth 2004; 14 (07) 607-609
    CrossrefPubMedGoogle Scholar
  • 2 Welters A, Lerch C, Kummer S. et al. Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers. Orphanet J Rare Dis 2015; 10 (01) 150
    CrossrefPubMedGoogle Scholar
  • 3 Demirel F, Unal S, Çetin II, Esen I, Arasli A. Pulmonary hypertension and reopening of the ductus arteriosus in an infant treated with diazoxide. J Pediatr Endocrinol Metab 2011; 24 (7-8): 603-605
    CrossrefPubMedGoogle Scholar
  • 4 Herrera A, Vajravelu ME, Givler S. et al. Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide. J Clin Endocrinol Metab 2018; 103 (12) 4365-4372
    CrossrefPubMedGoogle Scholar
  • 5 Nebesio TD, Hoover WC, Caldwell RL, Nitu ME, Eugster EA. Development of pulmonary hypertension in an infant treated with diazoxide. J Pediatr Endocrinol Metab 2007; 20 (08) 939-944
    CrossrefPubMedGoogle Scholar
  • 6 Timlin MR, Black AB, Delaney HM, Matos RI, Percival CS. Development of pulmonary hypertension during treatment with diazoxide: a case series and literature review. Pediatr Cardiol 2017; 38 (06) 1247-1250
    CrossrefPubMedGoogle Scholar
  • 7 FDA Drug Safety Communication, FDA Warns about a Serious Lung Condition in Infants and Newborns Treated with Proglycem (Diazoxide) [press release]. Food and Drug Administration. Maryland, USA: 2015
    Google Scholar
  • 8 Thornton P, Truong L, Reynolds C, Hamby T, Nedrelow J. Rate of serious adverse events associated with diazoxide treatment of patients with hyperinsulinism. Horm Res Paediatr 2019; 91 (01) 25-32
    CrossrefPubMedGoogle Scholar
  • 9 Gray KD, Dudash K, Escobar C. et al; Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee. Prevalence and safety of diazoxide in the neonatal intensive care unit. J Perinatol 2018; 38 (11) 1496-1502
    CrossrefPubMedGoogle Scholar
  • 10 Pediatrics AAo. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics 2011; 127 (03) 575-579
    CrossrefPubMedGoogle Scholar
  • 11 Silvani P, Camporesi A. Drug-induced pulmonary hypertension in newborns: a review. Curr Vasc Pharmacol 2007; 5 (02) 129-133
    CrossrefPubMedGoogle Scholar
  • 12 Yildizdas D, Erdem S, Küçükosmanoglu O, Yilmaz M, Yüksel B. Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. Adv Ther 2008; 25 (05) 515-519
    CrossrefPubMedGoogle Scholar